Polypill Products Market Estimated to Record Highest CAGR by 2027

June 6, 2020
Rohinic

Polypill Products Market: Introduction

According to the report, the global polypill products market was valued at US$ 29.7 Bn in 2018 and is projected to expand at a CAGR of ~2% from 2019 to 2027. Polypill is a fixed dose drug combination used in the treatment of various chronic diseases. This combination pharmacotherapy offers the potential to decrease the incidence and prevalence of cardiovascular and other diseases. Polypill improves patient compliance, thereby increasing the adoption of these products. This is likely to boost the growth of the global polypill products market. Moreover, ease of dosage understanding for elderly patients and increase in usage of polypill products are the major advantages offered by polypill products over other formulations. Combination therapy is more effective than a single substance with an acceptable safety profile. North America dominated the global polypill products market in 2018 and the trend is anticipated to continue during the forecast period. Strategies adopted by key players such as product approval & launch and merger & acquisition, well-established health care infrastructure, and early adoption of advanced therapeutics boost the growth of the polypill products market in the region.

Planning To Lay Down Future Strategy? Request Brochure Of Polypill Products Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74160

Asia Pacific is likely to be a highly lucrative market for polypill products. The market in the region is expected to expand at a high CAGR during the forecast period. Government initiatives in developing countries toward modernization of health care infrastructure, rise in awareness about advanced therapeutics, and increase in patients with chronic diseases are anticipated to fuel the growth of the polypill products market in Asia Pacific.

Surge in Number of Chronic Disease Patients to Drive Polypill Products Market

Sedentary lifestyle and unhealthy diet lead to chronic diseases. Diabetes mellitus and cardiovascular & infectious diseases are the leading causes of death globally. According to the European Society of Cardiology, 424.9 million people had diabetes across the world in 2017 and the number is expected to increase to 628.6 million by 2045. According to the World Health Organization, tuberculosis is among the top 10 causes of death globally. In 2018, an estimated 10 million people fell ill with tuberculosis across the globe. The application of polypill products in various chronic conditions has opened a promising avenue for the growth of the global polypill products market. Moreover, rise in availability of advanced treatment options and specialty care services boost the life expectancy rates across the world. This, in turn, increases the geriatric population. Surge in the geriatric population is anticipated to drive the global market.

Article Categories:
HEALTH

Leave a Comment